These data are consistent with what was seen in ER+ breast cancer cells expressing shRNA sequences against Mcl-1 and treated with ABT-263 (Figure 5C), which increased caspase 3/7 activity to a greater extent than Mcl-1 knockdown alone or ABT-263 treatment alone (Figure 5D). The gene discussed is MCL1; the disease is breast carcinoma.